

A Review on Hyperuricemia and the Worldwide Risk of Cardiovascular Disease Current Research and Future Preventive Strategies

Arjun Dahal¹, G. Sivakumar², S. Ramesh Babu³

Students^{1, 2}, Asst. Professor³

Department of Pharmaceutics

JKKN College of Pharmacy

Corresponding Author's E-mail: arjundahal548@gmail.com¹

Abstract

Over the last several years, scientific study has focused on the possible significance of hyperuricemia as a cardiovascular risk factor; the major focus has been on persistently elevated plasma uric acid levels. Although some studies have not found a strong link between hyperuricemia and cardiovascular risk, the majority of scientific evidence agrees that hyperuricemia is important in determining cardiovascular events and the development of other risk factors, which are frequently associated with only moderately elevated serum uric acid levels. The pathophysiological mechanisms behind this connection include mostly hyperuricemia-induced endothelial dysfunction, as well as inflammatory and oxidative stress caused by high blood uric acid levels. Early detection, follow-up, and preventative measures, as well as successful hyperuricemia therapy, are especially suggested in patients with additional concurrent cardiovascular risk factors. Urate-lowering medication should aim to achieve a serum uric acid level of less than 6 mg/dL (360 mol/L), while in high-risk individuals, the lowest feasible value of uric acid is preferable.

Keywords: Cardiovascular Disease, Worldwide Risk, pathophysiological Mechanisms, Hyperuricemia Therapy

INTRODUCTION

Cardiovascular risk is a group of characteristics that predispose to and raise the risk of cardiovascular events, namely cardiac ischemic disease and stroke. These risks include hypertension, diabetes, overweight/obesity, dyslipidemia, metabolic syndrome, tobacco use, and others. Over the last several years, scientific study has focused on the possible involvement of hyperuricemia as a cardiovascular risk factor; the major focus has been on persistently elevated plasma uric acid levels.

Uric acid, a heterocyclic organic molecule, is expelled in urine as the last oxidation result of exogenous and endogenous purine metabolism. Endogenous uric acid synthesis comes mostly from the liver and intestines and accounts for the majority of circulating uric acid (600-700 mg daily); food and animal proteins add to the exogenous purine pool (100-200 mg daily). In humans, the enzyme Xanthine oxidoreductase catalyses two terminal purine catabolism processes, resulting in the synthesis of uric acid from xanthine and hypoxanthine, which are created from other purines, chiefly adenine and guanine. Urate is mostly present in the extracellular compartment as monosodium urate, with a low solubility

limit of roughly 6.8 mg/dL (404 mol/L). The kidney filters the majority of the circulating uric acid, and around 90% of the filtered load is routinely reabsorbed through the proximal tubules of nephrons.

Renal excretion of uric acid represents approximately 60–70% of total uric acid excretion from the body; a smaller proportion of uric acid is secreted in the intestine, and is further metabolized by resident gut bacteria in a process termed Asymptomatic hyperuricemia is widespread and does not generally proceed to clinical Gout, a chronic inflammatory arthritis characterised by a purine metabolic problem that results in hyperuricemia. Acute uric acid nephropathy, uric acid nephrolithiasis, and chronic urate nephropathy are all possible consequences of hyperuricemia. There is evidence that persistent high uricemia behaves similarly to other conventional cardiovascular risk factors that are frequently linked with hyperuricemia, implying the possibility of a pathogenetic connection. Furthermore, hyperuricemia is more common in subjects with poor blood pressure control, as well as those with a higher degree of obesity and lower HDL-cholesterol plasma levels.

Scientific evidences

In 1999, data from the Framingham Heart Study, that examined a possible relation of serum uric acid levels to cardiovascular disease, concluded that uric acid does not have a causal role in the development of coronary heart disease, death from cardiovascular disease, or death from all causes.

Any apparent association with these outcomes were probably due to the association of uric acid levels with other risk factors. However, one year later, results from the NHANES I study showed that increased uric acid levels had a positive relationship to cardiovascular mortality and were independently and significantly associated with the risk of cardiovascular mortality. Afterwards, data from a prospective study and meta-analysis stated that serum uric acid levels is unlikely to enhance usefully the prediction of coronary artery disease and this humoral parameter is unlikely to be a major determinant of the disease in general populations. More recently, two meta-analysis, have reported that hyperuricemia may lead to a modest increment in the risk of stroke incidence and mortality and increases the risk of all-cause mortality and cardiovascular mortality.

On the other hand, beyond these conflicting results, it is undeniable that there is a lot of evidence that shows the link between high plasma levels of uric acid and cardiovascular risk. Animal , and clinical studies, have shown as hyperuricemia is associated with high blood pressure and with increased future risk of incident hypertension, independent of other risk factors; this risk appears more pronounced in younger individuals and women. Elevated serum uric acid is also independently associated with left ventricular mass index. Although a recent meta-analysis states that hyperuricemia may modestly increase the risk of hypertension incidence, consistent with a dose- response relationship, high plasma levels of uric acid were identified as independent predictive factors of hypertension development. A significant epidemiological correlation was also found between hyperuricemia, insulin resistance and other components of metabolic syndrome, moreover, serum uric acid levels are positively associated with the development of type 2 diabetes regardless of various study characteristics. In patients with insulin- resistance the increase in serum urate has often been considered to be secondary; however, in a long- term prospective study high levels of serum uric acid were found to be a

strong and independent predictor of incident metabolic syndrome. Moreover, a recent metanalysis provided strong evidence that hyperuricemia is a risk factor for developing type 2 diabetes in middle-aged and older people, independent of other established risk factors, especially metabolic syndrome components. Although these evidences suggest that hyperuricemia may play a pathophysiological role in glucose dysmetabolism, further research should attempt to determine whether it is effective to utilize uricemic plasma levels as a predictor of type 2 diabetes for its primary prevention. It has been also found that serum uric acid concentration is associated with microalbuminuria, glycated haemoglobin and carotid intima-media thickness in type 2 diabetics. In two recent italian longitudinal studies of a cohort of type 2 diabetics, mild hyperuricemia was found strongly associated with the risk of chronic kidney disease and increased serum uric acid is found to be an independent predictor factor of this complication. Randomized trials have also shown that reducing hyperuricemia by anti-hyperuricemic treatment leads to significant improvement in endothelial function this effect has been observed in diabetic patients with and without hypertension .

Moreover, long-term and high- dose therapy with the anti-hyperuricemic drug Allopurinol has allowed to achieve significant improvement in glycated hemoglobin values in type 2 diabetic patients. These data might well hypothesize a role of hyperuricemia even in the determinism of vascular complications of diabetes.

In addition, correlations were found between hyperuricemia and microvascular damage in kidney and it has been shown that hyperuricemia is also an independent risk factor for the development of chronic renal dysfunction in general population, in patients with hypertension and in diabetics.

Potential Pathogenetic Mechanisms

Pathophysiological mechanisms underlying the association between hyperuricemia and cardiovascular risk mainly include a hyperuricemia- induced endothelial dysfunction. The main determinants of vascular damage are the activation of the renin–angiotensin–aldosterone system and the production of reactive oxygen species resulting in cytokines production and in reduced endothelial bioavailability of nitric oxide. Uric acid has pro-inflammatory activity by stimulating the production of

Interleukin-1beta, Interleukin-6, Tumor necrosis factor- alfa and other cytokines. Another possible pathogenetic mechanism that can explain the vascular damage uric acid- related is the hyperactivity of the enzyme Xanthine oxido- reductase observed in hyperuricemic patients. Xanthine oxido- reductase catalyzes the last two steps of purine catabolism, the oxidation of hypoxanthine to xanthine and the oxidation of xanthine to uric acid. This enzyme exists in two forms: Xanthine dehydrogenase, which prefers NAD⁺ as electrons acceptor, and Xanthine oxidase, which generates electrons that are transferred directly to molecular oxygen; as a result of these reactions are produced two reactive oxygen species, superoxide anion and hydrogen peroxide, that contribute to amplify the oxidative stress and endothelial dysfunction.

In summary, hyperuricemia negatively affect vascular function by exerting pro-oxidant effects and by decreasing nitric oxide bioavailability, thus inducing inflammation and endothelial dysfunction, which may promote hypertension, diabetes, metabolic syndrome, nephropathy and cardiovascular disease.

Anti-hyperuricemic treatment and serum uratic target

There is no universally accepted definition of hyperuricemia. A physiochemical definition of hyperuricemia, based upon the solubility limit of urate in body fluids is widely preferred over a statistical definition because of the non-normal distribution of serum urate concentrations in most populations. This physicochemical definition corresponds to urate concentrations exceeding about 6.8-7 mg/dL (404- 416 μ mol/L), as measured by automated enzymatic (uricase) methods in routine clinical laboratory use; these values are approximately 1 mg/dL (60 μ mol/L) lower than those obtained with colorimetric methods.

Therapeutic approach of hyperuricemia, and its prevention, include lifestyle and dietary recommendations. Since high uric acid levels are often associated with metabolic syndrome, weight reduction with daily exercise should be encouraged to prevent hyperuricemia by reducing insulin resistance. Changes in eating habits and in nutritional style would help reduce uric acid levels; low intake of dietary purine as red meat, animal entrails, crustacean and high-purine vegetables, as asparagus, spinach, peas, cauliflower or

mushrooms, is recommended. Heavy drinking, ethanol and high fructose corn syrup-sweetened sodas should be avoided; whereas moderate drinking, sweet fruits, and seafood intake, particularly oily fish, should be tailored to the individual, considering their anticipated health benefits against cardiovascular diseases. Dairy products, vegetables, nuts, legumes, fruits (less sugary ones), and whole grains are healthy choices for the comorbidities of hyperuricemia and may also help prevent it by reducing insulin resistance. Adequate hydration may be useful to maintain a high urine output of at least 2 L daily; supplement of potassium citrate and occasionally sodium bicarbonate may be required to alkalinize the urine and to increase the solubility of uric acid. Folate intake, vitamin C supplementation and coffee consumption seem associated with a lower risk of incident gout, while thiazide and loop diuretics can increase blood uric acid levels by interfering with renal clearance..

Allopurinol, a competitive inhibitor of Xanthine oxido- reductase, is the most widely used anti-hyperuricemic agent, though not all patients are able to achieve a sufficient therapeutic response. Allopurinol can be used in almost any hyperuricemic state and the usual

maintenance dose for adults is 200-300 mg once-daily; however a dose adjustment is required in patients with chronic renal failure because a higher incidence of adverse effects is observed if the dose is not adjusted. Allopurinol is well tolerated, but potential severe or fatal hypersensitivity reactions may develop; hepatotoxicity, bone marrow depression, and interstitial nephritis are rare but serious side effects of Allopurinol. As well as being the most widely used anti-hyperuricemic, Allopurinol is also the most studied agent. Several studies have shown that anti-hyperuricemic treatment with Allopurinol has allowed to achieve a reduction in systolic and diastolic blood pressure values], regression of left ventricular mass in type 2 diabetic patients and a prolonged exercise capability in patients with chronic stable angina. It has also been shown that Allopurinol slows down the progression of renal failure in patients with chronic kidney disease . At last, as already mentioned, Allopurinol allows to obtain a significant improvement in endothelial function, by reducing oxidative stress in the vasculature and improving endothelium-dependent dilation. Another novel Xanthine oxido- reductase inhibitor, approved by the US Food and Drug Administration (FDA) in 2009 for long-

term treatment of hyperuricemia in patients with gout, is Febuxostat. In the CONFIRMS trial, a comparative study between Febuxostat and Allopurinol, Febuxostat 40 mg daily was statistically not inferior to Allopurinol 300 mg daily in lowering uric acid levels in patients with normal renal function, while Febuxostat 80 mg daily proved superior to both in such patients ($p < 0.001$); moreover, in patients with mild-to-moderate renal failure, Febuxostat at any dose was superior to Allopurinol in lowering uric acid levels and no dose adjustment was required in these patients. Although in the CONFIRMS study cardiovascular event rates were 0.0% for Febuxostat 40 mg and 0.4% for both Febuxostat 80 mg and Allopurinol 300 mg, some previous studies have identified cardiovascular events during Febuxostat treatment so that large ongoing trials are comparing the cardiovascular safety of Febuxostat versus Allopurinol. In the FLORENCE study, a recent large adult trial carried out in tumor lysis syndrome prevention, Febuxostat at fixed dose of 120 mg daily has also achieved a significant superior serum uric acid control in comparison to Allopurinol, with comparable renal function preservation and safety profile.

Other novel anti-hyperuricemic agents are Rasburicase, Pegloticase and Lesinurad; Rasburicase, is a recombinant urate oxidase that facilitates the conversion of urate to a more soluble product, allantoin. It is approved, at a dose of 0.2 mg/ kg daily as a 30-min infusion, in preventing complications of hyperuricemia for patients at high risk of tumor lysis syndrome. Pegloticase is a recombinant, pegylated, uric acid-specific enzyme, administered by intravenous infusion that catalyzes the oxidation of uric acid to allantoin. It is approved for use in adults with chronic gout that is refractory to conventional therapy. During Phase-3 trials with Pegloticase were reported three cases of heart failure exacerbation and a case of nonfatal myocardial infarction; high cost and safety profile might limit its use in clinical practice. Lesinurad is an oral selective uric acid reabsorption inhibitor approved by the FDA for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a Xanthine oxidoreductase inhibitor alone. It reduces hyperuricemia by inhibiting the urate transporter protein URAT1 that is responsible for the majority of the renal reabsorption of uric acid; moreover, Lesinurad also inhibits organic anion transporter OAT4, a uric

acid transporter involved in diuretic-induced hyperuricemia. Administration of Lesinurad may be associated with an increased serum creatinine levels therefore renal function should be assessed before initiating therapy and periodically thereafter; more frequent monitoring is required for an estimated creatinine clearance below 60 mL/min and therapy should not be started if creatinine clearance is below 45 mL/min. Lesinurad is not approved for asymptomatic hyperuricemia and it is contraindicated for increased uric acid levels resulting from tumor lysis syndrome. Other uricosuric agents that act on the proximal tubules in the kidneys, where they interfere with the reabsorption of uric acid through blocking URAT1, are Probenecid, Sulfinpyrazone and Benzbromarone. Although these uricosuric agents provide the most time honoured approach to the control of hyperuricemia, their place in the armamentarium has been eclipsed by that of Xanthine oxidase inhibitors .

At last, it is worth noting that some drugs with other primary uses, as Losartan, Atorvastatin, Simvastatin and Fenofibrate, can have known uricosuric properties; these findings should be considered in

hyperuricemic patients with comorbidity as hypertension and dyslipidemia.

However, regardless of the treatment used, urate-lowering therapy should be aimed at reaching at least a serum uric acid level below 6 mg/dL (360 μ mol/L) and this value is considered the minimum serum urate target . Actually we have found that the relationship between uric acid and cardiovascular events is evident not only in the presence of overt hyperuricemia but also for moderately increased levels of uric acid or for values corresponding to the upper limit of the actual normal range. Moreover, a significant independent association between serum urate concentrations and subsequent hazard of incident hypertension was reported even at concentrations below the conventional hyperuricemia threshold of 6.8 mg/dl [20]. At last, the presence of only moderately increased serum uric acid levels ($>$ 5.3 mg/dL in women and $>$ 7.0 mg/dL in men) was also associated with a significantly increased risk of developing type 2 diabetes mellitus.

We retain that, regarding the control of serum urate, particularly in patients with other cardiovascular risk factors, the lowest possible value of uric acid is better.

CONCLUSION

Although some studies have not found a strong link between hyperuricemia and cardiovascular risk, the majority of scientific evidence agrees that hyperuricemia plays an important role in determining cardiovascular events and the development of other risk factors, which are frequently associated with moderate increases in serum uric acid levels. Early detection, follow-up, and preventative measures, as well as successful hyperuricemia therapy, are especially suggested in patients with additional concurrent cardiovascular risk factors. Urate-lowering therapy should aim to achieve a serum uric acid level of less than 6 mg/dL (360 μ mol/L); however, because the relationship between hyperuricemia and cardiovascular events is evident also for moderately increased levels of uric acid or values corresponding to the upper limit of the actual normal range, the lowest possible value of uric acid is better in high risk patients.

REFERENCES

1. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, et al. (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. *Eur J Epidemiol* 18: 523-530. Link: <https://goo.gl/wLaHDM>
2. Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, et al. (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. *Nephrol Dial Transplant* 23: 1179-1185. Link: <https://goo.gl/8W6HMo>
3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil* 2: S1-113. Link: <https://goo.gl/5KescS>
4. Marangella M (2005) Uric acid elimination in the urine.

- Pathophysiological implications. Contrib Nephrol 147: 132-148. Link: <https://goo.gl/vGyBCD>
5. Maseoud D, Rott K, Liu-Bryan R, Agudelo C (2005) Overview of hyperuricaemia and gout. Curr Pharm Des 11: 4117-4124. Link: <https://goo.gl/rxjrML>
 6. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A (2012) Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 59: 235-242. Link: <https://goo.gl/A4FdPS>
 7. Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J (2005) Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2: e76. Link: <https://goo.gl/5kNV7g>
 8. Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63: 102-110. Link: <https://goo.gl/n8Umaq>
 9. Juraschek SP, Kovell LC, Miller ER, Gelber AC (2013) Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One 8: e56546. Link: <https://goo.gl/rK6Gqs>
 10. Shah A, Keenan RT (2010) Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 12: 118-124. Link: <https://goo.gl/AqV4Da>
 11. <https://goo.gl/AqV4Da>
 12. Xu W, Huang Y, Li L, Sun Z, Shen Y, et al. (2016) Hyperuricemia induces hypertension through activation of renal epithelial sodium channel (ENaC). Metabolism 65: 73-83. Link: <https://goo.gl/voJWfR>
 13. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, et al. (2009) Hyperuricemia and risk of stroke: a systematic review and meta-

analysis. Arthritis Rheum 61: 885-

892. Link: <https://goo.gl/89q29v>

14. Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 7-13. Link: <https://goo.gl/f4xTnd>

15. Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J (2005) Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2: e76. Link: <https://goo.gl/5kNV7g>